Background: Treatment of skin and superficial soft tissue infections with topically applied antibiotics is a controversial topic, because only few clinical studies exist and target site concentrations after topical treatment are widely unknown.
Introduction
In recent decades a significant increase in skin and soft tissue infections (SSTIs) has been observed. 1 Seventy percent to 75% of all SSTIs are treated in the outpatient setting, accounting for the third most common diagnosis after chest pain and asthma in emergency care. 2 Staphylococcus aureus continues to be the leading cause of both uncomplicated and complicated SSTIs. 1 In addition, recent epidemiological studies have shown an increase in both community-acquired as well as healthcare-associated MRSA, 3, 4 which has emerged to be the most common identifiable pathogen responsible for severe SSTIs. 5 Gentamicin is a hydrophilic, 6 bactericidal aminoglycoside active against many strains of Gram-positive and Gram-negative bacteria including S. aureus, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. [7] [8] [9] Among others, it is systemically used in the treatment of bacteraemia, urinary tract infections and chest infections, 9 and topically in ophthalmology and in the field of dermatology for treatment of impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis or pyoderma gangrenosum. Furthermore it is approved for treating secondary skin infections as infectious eczematoid dermatitis, pustular psoriasis, pustular acne or other bacterial super-infections. 7 Beside gentamicin, several antibiotics, including bacitracin, retapamulin and mupirocin, are available for topical treatment of SSTIs. Indeed, avoiding systemic side effects by topical administration, e.g. nephrotoxicity for aminoglycosides, appears tempting. IDSA guidelines from 2014 recommend mupirocin and retapamulin for the treatment of bullous and non-bullous impetigo, 10 mupirocin is included in a Canadian guideline for treatment of community-acquired MRSA SSTIs such as folliculitis and furuncles, 11 and in the treatment of acne topical antibiotics are recommended in combination with benzoyl peroxide. 12 Treatment numbers with topical antibiotics have been slowly increasing for several years in the UK, reporting 4.7 million prescriptions in 2015. 13 Moreover, some topical antibiotics are available over the counter in Europe and the USA 14, 15 and are advertised in popular scientific media. 16 A strong limitation for all topical treatments is based on the corneal layer of the skin, which forms a strong barrier against passive drug penetration and lack of transdermal drug delivery has thereby been shown for other classes of topically used drugs, e.g. diclofenac. 17, 18 Despite frequent doubt being raised whether topically administering antibiotics lead to efficient target site concentrations, dermal concentration versus time profiles after topical administration remain unknown. However, sufficient antibiotic exposure is a prerequisite to avoid development of bacterial resistance. 19 Indeed, previously published data show that topical antibiotics are associated with an increase in resistance. [20] [21] [22] [23] [24] [25] As insufficient transdermal drug delivery is a widely discussed topic, different pharmacological (uptake enhancers) and physicochemical methods (e.g. iontophoresis 26 ) have been explored for increasing tissue penetration of topical administered substances. Microporation is a method currently used as part of the treatment of various skin conditions such as actinic keratosis 27 and was used to enhance delivery of topical administered substances such as lidocaine, 28 diclofenac 29 and basiliximab. 30 Skin penetration of antibiotics in combination with microporation has not been studied yet.
By determining the tissue penetration and bioavailability of gentamicin after topical administration using microdialysis, the present study aims to re-evaluate critically the pharmacokinetics (PK) of topical antibiotic therapy and potentially identify subtherapeutic concentrations as the underlying cause for clinical failure and for development of bacterial resistance. Microporation was evaluated as innovative enhancement method for transdermal delivery of topical antibiotics.
Materials and methods
This prospective, single-centre study was conducted in full accordance with the principles of the Declaration of Helsinki (revised version of Brazil in 2013), the ICH harmonized tripartite guideline for Good Clinical Practice, the EMA Note for Guidance on Good Clinical Practice, the Austrian Drug Law (Arzneimittelgesetz, AMG) and the Austrian Investigational Medical Devices Act. The Ethics Committee of the Medical University of Vienna and the Austrian Agency for Health and Food Safety approved and authorized this study (EC number 1633/2015, EudraCT number 2015-003037-10). Informed consent was sought from all subjects.
Study population
Six healthy volunteers were included in this single-centre study performed at the Department of Clinical Pharmacology in Vienna, Austria. Study subjects were enrolled after a screening visit, which included physical examination, blood sampling, urine analysis, ECG and vital signs. Main exclusion criteria were evidence of anaemia, any contraindication for administration of gentamicin or laser application, use of prescription or nonprescription drugs including topically applied ones within 7 days or 10 times the elimination half-life prior to the study day, any allergies or history of hypersensitivity reaction following administration of any medicine and any acute or chronic illness or abnormality considered as clinically relevant in the investigator's opinion.
Study substance
Gentamicin (Refobacin V R ) cream was obtained from Almirall Hermal GmbH. One gram of Refobacin V R cream contains 1.67 mg of gentamicin sulphate, which is equivalent to 1 mg of gentamicin. 31 In this study, 500 mg of Refobacin V R were administered in a thin layer to a predefined area measuring 2.8%9.8 cm on the upper thigh. This was administered as a single dose on the morning of the study day.
P.L.E.A.S.E. laser system P.L.E.A.S.E. Professional (Painless Laser Epidermal System) from Pantec Biosolutions AG (Liechtenstein) is a CE certified medical device based on an Er:YAG laser to generate micropores in the skin. The device emits light with a wavelength of 2940 nm and therefore breaks the stratum corneum by creating micropores with a user defined depth and density with a minimal coagulation zone. In this study, a density of 8%, 2 pulses per pore, repetition rate of 100 Hz, pulse length of 225 ls and estimated depth of micropores of 100-150 lm were applied. One field of administration measures 1.4%1.4 cm. To create a greater administration area, we applied the laser on a predefined area of 2.8%9.8 cm. Microporation was performed before microdialysis catheters were inserted in the dermis to prevent damage of the microdialysis catheters.
Microdialysis
The gentamicin concentration was determined in tissue using microdialysis. Microdialysis is a clinical research method that allows quantification of the unbound fraction of a substance in the interstitial space fluid. Microdialysis catheters with a semipermeable membrane on the tip of each probe can be inserted into the tissue of interest and are constantly perfused with physiological solution at a predefined flow rate. In this study, two microdialysis catheters CMA 66 (M Dialysis AB, Solna, Sweden) with a cutoff membrane of 20 kDa were used per period and subject, introduced in the dermis below the treatment area and perfused at a flow rate of 2.0 lL/min. A fraction of the substance present in the extracellular fluid (C tissue ) penetrates passing the semipermeable membrane via passive diffusion into the dialysate and is quantified in the microdialysate (C dialysate ). As equilibrium between extracellular tissue fluid and the perfusion medium is incomplete a probe calibration was performed at the end of the PK sampling period using the retrodialysis method. The principles of this method rely on the fact that the exchange process is equal in both directions. By perfusing the catheter with a known concentration of gentamicin (50 mg/L) in vivo recovery values were calculated as: recovery (%) " 100 # (100 % analyte concentration out /analyte concentration in ), which finally allows calculation of the interstitial concentrations according to the equation C tissue " C dialysate /recovery. The method has been previously described in detail. 32, 33 Procedure and PK This PK study was performed in a randomized crossover design with two periods. Healthy subjects underwent a screening visit, two study days and a final visit. During one period the healthy volunteers had gentamicin administered on intact skin, during the other the administration of the study drug was performed on microporated skin for comparison of tissue penetration and systemic bioavailability of gentamicin with and without microporation. Study subjects were randomized as to whether they would receive microporation on study day 1 or study day 2 and the periods were separated by a washout period of 7 days.
On both study days a baseline plasma and microdialysate sample (from two microdialysis catheters per subject and period) were collected. After study drug administration at timepoint 0, blood sampling was performed hourly for 6 h. Congruently microdialysate sampling was performed hourly over 6 h (between 0 and 1 h, 1 and 2 h, 2 and 3 h, 3 and 4 h, 4 and 5 h, and Oesterreicher et al.
5 and 6 h) after gentamicin administration including a 30 min baseline sampling period before drug administration. Retrodialysis was performed before removal of the probes.
After blood sampling in lithium heparin tubes the samples were immediately centrifuged at room temperature and at 2000 g for 10 min to gain plasma. Two aliquots of plasma as well as all microdialysate samples were snap frozen at #20 C, before samples were stored at #80 C at the end of one study day until the time of analysis.
Chemical analysis
Gentamicin concentrations in microdialysate and plasma were analysed using a commercially available competitive enzyme immunoassay (Shenzen Lvshiyuan Biotechnology, Shenzen, China). Briefly, 50 lL of standard or diluted sample was placed into each well (pre-coated with sheep antirabbit IgG) followed by 50 lL of enzyme-labelled gentamicin (horseradish peroxidase) and 50 lL of rabbit anti-gentamicin. The microplate was then shaken for several seconds and incubated at 25 C for 30 min. The contents of the microplate were discarded and the wells washed five times with 250 lL of washing solution (provided by the manufacturer). After adding 50 lL of tetramethylbenzidine to each well, the microplate was further incubated for 15 min in the dark. The reaction was stopped by adding 50 lL of stop solution (sulphuric acid) to each well. The absorbance values were determined at 450 nm using an EnSpire V R 2300 Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). All standards and samples were run in duplicate with the mean values used for analysis. Calibration of the assay was accomplished by spiking drug-free human plasma and microdialysate with standard solutions of gentamicin to obtain a concentration range of 0.01-10 ng/mL (average correlation coefficients .0.98). The limit of quantification for gentamicin in plasma and microdialysate was 0.01 ng/mL. Coefficients of accuracy and precision for this compound were ,8%.
PK and statistical analysis
Using a commercially available computer program (Kinetica; Innaphase), the following PK parameters were calculated from data gained from subcutis and plasma: C max , T max , AUC from 0 to 6 h (AUC 0-6 ). Values are given as mean + SD of six healthy volunteers or of 11 and 12 microdialysis catheters-due to malfunction of one microdialysis catheter in the laser period.
Intra-subject variability between two microdialysis catheters of one subject and inter-individual variability were calculated by coefficient of variation in Microsoft Excel using AUC values. For PK/pharmacodynamic (PD) consideration the ratio of C max values in tissue and plasma to the epidemiological cut-off (ECOFF) values for S. aureus and P. aeruginosa provided by EUCAST were calculated. All graphs in this paper were drawn using the commercially available program 'OriginPro' (OriginLab Corporation).
Results
Six healthy male volunteers completed this PK study (mean age 28.5+5.1 years, height 181.2+4.2 cm, weight 79.8+3.3 kg). Administration of gentamicin was well tolerated. Although adverse events occurred in four of six healthy volunteers these were mainly local reactions and included haematoma at the insertion site of microdialysis catheters (n " 4), pruritus (n " 2) and stinging (n " 1) after study drug administration on microporated skin, and pain after microdialysis catheter insertion at the insertion site (n " 1). Furthermore, one other subject suffered from gastritis (n " 1). There were no serious adverse events. Figure 1 gives an impression of the study drug administration area by showing the upper thigh after microporation, insertion of microdialysis catheters and study drug administration in a predefined and marked area. Table 1 shows PK parameters of gentamicin in subcutis and plasma. In plasma only after administration on microporated skin, gentamicin could be determined with C max , T max and AUC 0-6 in plasma of 4.8+1.5 ng/mL, 3.5+1.0 h and 19.9+7.2 ngÁh/mL, but no systemic bioavailability was detectable after administration on intact skin [lower limit of quantification (LLOQ) was 10 pg/mL].
In dermis, C max , T max and AUC 0-6 were 3.3+5.64 ng/mL, 2.6+2.1 h and 5.4+10.4 ngÁh/mL after administration on intact skin, and 474.2+555.3 ng/mL, 2.7+0.8 h and 1170.3+1311.9 ngÁh/mL after gentamicin administration to microporated skin. Therefore, microporation increased dermal C max .100-fold compared with administration on intact skin. Owing to a malfunction of one microdialysis catheter in the period of laser administration, the given values are mean values of 11 instead of 12 microdialysis catheters for this period. The mean in vivo recovery of 12 and 11 microdialysis catheters was 45% + 9.7% and 23% + 10.2% after administration of gentamicin on intact and microporated skin, respectively (P , 0.05). Time-concentration curves of tissue and plasma are shown as mean values in Figure 2 and for individual microdialysis catheters after gentamicin administration on microporated skin in Figure 3 .
The coefficient of variation was calculated for dermal concentrations showing that intra-individual variability, i.e. the variability between two microdialysis catheters in one subject, was smaller than the inter-individual variability and variability was lower for microporated than for intact skin. After administration on microporated skin the mean intra-and inter-individual variabilities were 0.59 and 1.12 compared with 0.99 and 1.92 after administration on intact skin, respectively. Correlating the C max and AUC values in plasma with those in dermis after microporation Spearman's r of Dermal gentamicin PK with and without microporation of the skin JAC 0.371 and 0.600 (P values of 0.468 and 0.208), respectively, were obtained (shown in Figure 4) .
Though enhancement of tissue penetration by microporation is evident, estimating target site efficacy by PK/PD parameters using ECOFF values still indicated insufficient tissue concentrations ( Table 2) . Ratios of C max in subcutaneous tissue to the ECOFF value for S. aureus (2 mg/L) were 0.002 and 0.237 after administration on intact and microporated skin, respectively. Ratios of C max in subcutaneous tissue to the ECOFF value for P. aeruginosa (8 mg/L) were 0.0004 and 0.059 after administration on intact skin and microporated skin, respectively.
Discussion
This study determined dermal concentrations and bioavailability of gentamicin after topical administration on intact skin as well as after microporation as the potential enhancement method for transdermal drug delivery. When comparing concentration versus time profiles of gentamicin with susceptibility of S. aureus and P. aeruginosa neither administration of gentamicin on intact skin nor the application on microporated skin could lead to concentrations over the respective ECOFF values.
In some studies efficacy of topical antibiotics such as mupirocin and retapamulin was equivalent to the efficacy of oral antibiotics in the treatment of impetigo. 10, 34 However, topical mupirocin was not more effective than its vehicle control in another study. 35 Likewise contradictory findings exist for the effect of topical antibiotics on wound healing. Fischer et al. 36 reported that a nonantibiotic control showed better healing after 4 weeks than an ointment containing chloramphenicol. Cameron et al. 37 showed no difference in complete healing between mupirocin ointment compared with a vehicle. Looking at PD results of topical antibiotics, mupirocin and fusidic acid were studied for their bactericidal effect on S. aureus and Streptococcus spp. in superficial skin infections showing eradication rates of at least 88%. 38 For topically administered gentamicin a porcine wound model was used to evaluate the S. aureus as cfu/g in biopsies and wound fluid after administration of topical gentamicin at different concentrations. High antibacterial activity was observed, however, solely at a high dose of 20 mg and not at the lower, clinically used doses. 39 While data regarding efficacy of topical antibiotics are at best heterogeneous, the risk of emergence of resistance due to the topical use of antibiotics is well described. In case of mupirocin, the development of resistance through cross-transmission and increased selective pressure was described. 20 This finding was in accordance with another study reporting an increase in resistance of MRSA to mupirocin from 3% to 65% after widespread use of mupirocin for controlling MRSA in hospitals for 3 years. 21 An epidemiological survey demonstrated a correlation between an increase in fusidic acid resistance of S. aureus in New Zealand from 17% to 29% within 14 years and a 4-fold increase in dispensing rates during the same time span. 22 Another study describes the acquisition of S. aureus resistant to gentamicin in 116 infants at an intensive care nursery to be significantly associated with the topical administration of gentamicin ointment. 25 Likewise, in Oesterreicher et al.
the field of ophthalmological topical antibiotic therapy, previously published studies report an increase in resistance rates among conjunctival flora after topical administration of different antibiotics. 23, 24 While many studies exist on tissue concentrations of antibiotics after systemic administration, evidence on actual skin and tissue concentrations of antibiotics after topical administration are sparse. Therapeutic subcutaneous concentrations after intravenous administration were described for moxifloxacin (inflamed and healthy tissue in diabetic patients and nondiabetic patients), 40 levofloxacin (inflamed and healthy) 41 and gentamicin. 42 Determining subcutaneous concentrations after topical administration was performed by Benfeldt and Groth 43 studying fusidic acid in subcutaneous tissue in healthy volunteers using microdialysis. However, all concentrations were below the quantification limit of 5 ng/mL. 43 After topical administration of paromomycin plus 0.5% gentamicin in patients with cutaneous leishmaniasis, plasma gentamicin were rarely evident using a quantification limit of 50.0 ng/mL for total gentamicin; in contrast to the PK of paromomycin, which showed a C max of 1000+750 ng/mL. 44 However, no data on actual subcutaneous concentrations after dermal administration of gentamicin as cream or ointment existed until now.
In this study, the use of the Er:YAG laser system increased tissue penetration $100-fold (C max 4.8 versus 474 ng/mL) by creating micropores and therefore breaking the stratum corneum of the skin. However, even after administration on microporated skin, dermal gentamicin concentrations were found to be in the ng/mL range while being far below the ECOFF values for WT S. aureus and P. aeruginosa resulting in C max /ECOFF ratios of 0.237 and 0.059 for S. aureus and P. aeruginosa, respectively ( Figure 2 and Table 2 ). Inadequate C max /ECOFF values indicate that even in strains without acquired resistance mechanisms the treatment with topical gentamicin could be ineffective and concentrations have to be considered to be clearly subtherapeutically. While the depth of micropores can be increased, one might assume that, once the stratum corneum as a main barrier is already broken, a further increase in depth might not increase tissue penetration substantially any further, so we must conclude that even by using this mechanical enhancement method for drug delivery no therapeutic concentrations could be achieved.
Chemical characteristics of antibiotics might also impact penetration into intact skin. Usually hydrophilic antibiotics are considered to have lower tissue penetration than lipophilic antibiotics. 45 However, not even for the lipophilic fusidic acid, quantifiable concentrations could be determined after topical administration in a previously performed microdialysis study. 43 As protein binding reduces penetration from substances from plasma into tissue, transdermal penetration might also be impacted by binding to surface proteins during diffusion through micropores. 46 However, as gentamicin does not show any plasma protein binding 47 relevant binding to other human proteins is also considered unlikely.
Microdialysis as a method for measuring dermal gentamicin concentrations is thought to be favourable compared with other methods, as in contrast to shave or punch biopsies it allows a minimally invasive determination of continuous concentration versus time profiles in tissue in vivo. The mean difference between two probes in each subject remained substantially smaller than the inter-individual variability, both with and without microporation, suggesting that results obtained by microdialysis were reliable. Dermal gentamicin PK with and without microporation of the skin JAC Interestingly, a significant difference in recovery values between microporated and intact skin was found; however, the reason for this difference remains unknown. Though correlation of C max and AUC data in plasma with those in tissue may appear significant looking at Figure 4 , Spearman's correlation coefficient did not show a significant result. A greater sample size would be necessary to validate this finding. The fact that solely PK after single but not after multiple doses has been studied has to be mentioned as a limitation of the study. However, due to the short half-life of gentamicin determined in this study of 1.19+0.97 and 1.36+0.54 h after administration on intact and microporated skin, respectively, accumulation by multiple dosing seems very unlikely. In this study, microdialysis catheters were inserted as superficially as possible, i.e. ,5 mm under the skin surface. Still, efficacy of topical antibiotics when treating more superficial infections, wounds or ulcers has not been considered in the present study.
In conclusion, this study demonstrates that topical administration of gentamicin does not lead to therapeutic dermal concentrations. Though microporation increased tissue penetration of gentamicin $100-fold, even these concentrations are deemed necessary for sufficient antimicrobial effects. Our results highlight the importance of determining target site PK of antibiotics independent of the administration route for estimating clinical activity. Topical antibiotics have been discussed controversially. Based on the present data, we discourage topical administration of antibiotics to avoid insufficient therapy and development of bacterial resistance to maintain sensitivity of bacteria to systemic antibiotic therapy.
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